News

  • 18 January 2013

    Santhera Pharmaceuticals (SIX: SANN) announced today that it has received a negative opinion on its Marketing Authorization Application (MAA) for Raxone® as a potential therapy for Leber’s Hereditary Optic Neuropathy (LHON). The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has notified Santhera that a narrow majority of CHMP members deemed Raxone® not approvable at this time. Santhera believes that the clinical benefit of Raxone® in patients in whom the medical need for treatment was most urgent had not been fully considered and therefore has decided to request a re-examination of the opinion.

  • 7 January 2013

    JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter-delivered aortic valve systems (TAVI) for the treatment of aortic valve disease, announced today that it has appointed veteran medical device executive Raymond W. Cohen as Executive Chairman of its Board of Directors.

  • 27 November 2012

    Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced the close of a USD 40.3 million/CHF 37.4 million series C financing. Led by new investor NGN Capital, the round drew large participation from all existing investors, including Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie, as well as multiple employees. Proceeds will be used to support the growth of a new direct sales organization in Europe; commercialization of the recently introduced third-generation TactiCath Quartz forcesensing catheter in the region; development of next generation products; completion of the TOCCASTAR investigational device exemption (IDE) clinical study follow-up and FDA approval submission for the TactiCath; and, the launch of the device in the United States.

  • 16 November 2012

    Santhera Pharmaceuticals (SIX: SANN)announced today that the opinion of the Committee for Medicinal Products for Human Use (CHMP) on its Marketing Authorization Application (MAA) for Raxone® in the treatment of Leber's Hereditary Optic Neuropathy (LHON) is expected to be obtained in early 2013.

  • 8 November 2012

    NeoMed Management is pleased to announce that Vessix Vascular, Inc., an emerging medical technology company in which NeoMed has been the lead investor since 2007, has agreed to be acquired by Boston Scientific Corp., a leading US headquartered medical device company, for up to $425M. The agreement calls for an upfront payment of $125M on closing and up to $300M in clinical and sales related payments.